A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

  1. Laubach, J.P.
  2. Moslehi, J.J.
  3. Francis, S.A.
  4. San Miguel, J.F.
  5. Sonneveld, P.
  6. Orlowski, R.Z.
  7. Moreau, P.
  8. Rosiñol, L.
  9. Faber, E.A.
  10. Voorhees, P.
  11. Mateos, M.-V.
  12. Marquez, L.
  13. Feng, H.
  14. Desai, A.
  15. van de Velde, H.
  16. Elliott, J.
  17. Shi, H.
  18. Dow, E.
  19. Jobanputra, N.
  20. Esseltine, D.-L.
  21. Niculescu, L.
  22. Anderson, K.C.
  23. Lonial, S.
  24. Richardson, P.G.
Revue:
British Journal of Haematology

ISSN: 1365-2141,  0007-1048

Année de publication: 2017

Volumen: 178

Número: 4

Pages: 547-560

Type: Article

DOI: 10.1111/BJH.14708 GOOGLE SCHOLAR lock_openAccès ouvert editor
La source de données: Scopus